The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EBMT 2020 | Current treatment landscape of DLBCL
Edmund Waller, MD, PhD, FACP, Division of Hematology/Oncology, Emory Clinic, Atlanta, GA, explores the current treatment landscape of diffuse large B-cell lymphoma (DLBCL), and discusses future approaches being developed, including earlier infusion of CAR T-cell therapies as evaluated in the BELINDA (NCT03570892) and TRANSFORM (NCT03575351) studies. Dr Waller also discusses polatuzumab vedotin, an antibody-drug conjugate that displays increased remission rates in relapsed/refractory lymphoma patients when compared to salvage bendamustine/rituximab. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
